CO2022016762A2 - Derivados de tetrazol como inhibidores de trpa1 - Google Patents
Derivados de tetrazol como inhibidores de trpa1Info
- Publication number
- CO2022016762A2 CO2022016762A2 CONC2022/0016762A CO2022016762A CO2022016762A2 CO 2022016762 A2 CO2022016762 A2 CO 2022016762A2 CO 2022016762 A CO2022016762 A CO 2022016762A CO 2022016762 A2 CO2022016762 A2 CO 2022016762A2
- Authority
- CO
- Colombia
- Prior art keywords
- tetrazole derivatives
- trpa1
- trpa1 inhibitors
- inhibitors
- tetrazole
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003536 tetrazoles Chemical class 0.000 title abstract 2
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 title 1
- 102100031366 Ankyrin-1 Human genes 0.000 abstract 1
- 101710191059 Ankyrin-1 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente divulgación proporciona algunos derivados de tetrazol que son inhibidores de potencial de receptor transitorio anquirina 1 (TRPA1) y que, por ende, son útiles para el tratamiento de las enfermedades que se pueden tratar mediante inhibición de TRPA1. Asimismo, se proporcionan composiciones farmacéuticas que lo contienen, y procesos para la preparación de dichos compuestos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20182987 | 2020-06-29 | ||
| PCT/EP2021/067467 WO2022002780A1 (en) | 2020-06-29 | 2021-06-25 | Tetrazole derivatives as trpa1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022016762A2 true CO2022016762A2 (es) | 2022-12-09 |
Family
ID=71401655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0016762A CO2022016762A2 (es) | 2020-06-29 | 2022-11-22 | Derivados de tetrazol como inhibidores de trpa1 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11891403B2 (es) |
| EP (1) | EP4171571A1 (es) |
| JP (1) | JP2023533189A (es) |
| KR (1) | KR20230028546A (es) |
| CN (1) | CN116157130A (es) |
| AR (1) | AR122778A1 (es) |
| AU (1) | AU2021301140A1 (es) |
| BR (1) | BR112022021386A2 (es) |
| CA (1) | CA3182143A1 (es) |
| CL (1) | CL2022003325A1 (es) |
| CO (1) | CO2022016762A2 (es) |
| CR (1) | CR20220668A (es) |
| DO (1) | DOP2022000270A (es) |
| EC (1) | ECSP22088958A (es) |
| IL (1) | IL299172A (es) |
| MX (1) | MX2022016272A (es) |
| PE (1) | PE20240594A1 (es) |
| TW (1) | TW202216729A (es) |
| WO (1) | WO2022002780A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022219012A1 (en) | 2021-04-14 | 2022-10-20 | Boehringer Ingelheim International Gmbh | 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017060488A1 (en) | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2022219012A1 (en) | 2021-04-14 | 2022-10-20 | Boehringer Ingelheim International Gmbh | 3h,4h,5h,6h,7h-pyrimido[4,5-b][1,4]oxazine-4,6-dione derivatives as trpa1 inhibitors |
-
2021
- 2021-06-24 US US17/356,782 patent/US11891403B2/en active Active
- 2021-06-25 JP JP2022578725A patent/JP2023533189A/ja active Pending
- 2021-06-25 CA CA3182143A patent/CA3182143A1/en active Pending
- 2021-06-25 IL IL299172A patent/IL299172A/en unknown
- 2021-06-25 BR BR112022021386A patent/BR112022021386A2/pt unknown
- 2021-06-25 MX MX2022016272A patent/MX2022016272A/es unknown
- 2021-06-25 KR KR1020237003323A patent/KR20230028546A/ko unknown
- 2021-06-25 CR CR20220668A patent/CR20220668A/es unknown
- 2021-06-25 PE PE2022003064A patent/PE20240594A1/es unknown
- 2021-06-25 AU AU2021301140A patent/AU2021301140A1/en active Pending
- 2021-06-25 WO PCT/EP2021/067467 patent/WO2022002780A1/en active Application Filing
- 2021-06-25 CN CN202180045923.7A patent/CN116157130A/zh active Pending
- 2021-06-25 EP EP21735302.8A patent/EP4171571A1/en active Pending
- 2021-06-28 AR ARP210101794A patent/AR122778A1/es unknown
- 2021-06-28 TW TW110123498A patent/TW202216729A/zh unknown
-
2022
- 2022-11-21 EC ECSENADI202288958A patent/ECSP22088958A/es unknown
- 2022-11-22 CO CONC2022/0016762A patent/CO2022016762A2/es unknown
- 2022-11-25 CL CL2022003325A patent/CL2022003325A1/es unknown
- 2022-11-30 DO DO2022000270A patent/DOP2022000270A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210403482A1 (en) | 2021-12-30 |
| TW202216729A (zh) | 2022-05-01 |
| EP4171571A1 (en) | 2023-05-03 |
| ECSP22088958A (es) | 2022-12-30 |
| CA3182143A1 (en) | 2022-01-06 |
| CN116157130A (zh) | 2023-05-23 |
| IL299172A (en) | 2023-02-01 |
| AR122778A1 (es) | 2022-10-05 |
| MX2022016272A (es) | 2023-02-09 |
| DOP2022000270A (es) | 2023-01-15 |
| BR112022021386A2 (pt) | 2023-01-10 |
| CR20220668A (es) | 2023-03-10 |
| KR20230028546A (ko) | 2023-02-28 |
| US11891403B2 (en) | 2024-02-06 |
| AU2021301140A1 (en) | 2022-11-10 |
| JP2023533189A (ja) | 2023-08-02 |
| WO2022002780A1 (en) | 2022-01-06 |
| PE20240594A1 (es) | 2024-03-21 |
| CL2022003325A1 (es) | 2023-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003329A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| CO2021004436A2 (es) | Derivados de anillo tricíclico condensado como inhibidores de la fosfatasa de homología a src 2 | |
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CL2021001508A1 (es) | Derivados de 2-oxoquinazolina como inhibidores de metionina adenosiltransferasa 2a | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| BR112021020637A2 (pt) | Derivados de tetra-hidro-1h-ciclopenta[cd]indeno como inibidores de fator -2(alfa) induzível por hipóxia | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| UY33430A (es) | Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer | |
| DOP2010000064A (es) | 2-anilinopurin 8-onas como inhibidores de ttk/mps1 para el tratamiento de trastornos proliferativos | |
| DOP2007000051A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes | |
| UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CL2023002633A1 (es) | Derivados de uracilo como inhibidores de trpa1 | |
| CO2022011258A2 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| CL2020001244A1 (es) | Inhibidores de inmunoproteasoma. | |
| DOP2022000270A (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| CL2023002635A1 (es) | Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1 | |
| CL2023000838A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| CL2023000837A1 (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| BR112023015342A2 (pt) | Derivados de 3h,4h-[2,3-d]-pirimidin-4-ona como inibidores de trpa1 | |
| CL2021001944A1 (es) | Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias | |
| CO2019001967A2 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CO2024000572A2 (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 |